OABI Stock Analysis: Buy, Sell, or Hold?
OABI - OmniAb, Inc. Common Stock
$4.71
0.38 (8.78%)
▲
5d:
+23.3%
30d:
+132.02%
90d:
+77.74%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When OABI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OABI is 27.6% above its trading range ($3.69). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: OABI is 27.6% above its trading range ($3.69). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: OABI is currently trading at $4.71, which is considered extended relative to its 30-day fair value range of $1.87 to $3.69.
Technical Outlook: Technically, OABI is in a uptrend. The price is approaching resistance at $4.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: OABI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.67 (+77.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OABI is in a uptrend. The price is approaching resistance at $4.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: OABI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.67 (+77.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.87 -
$3.69
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+27.6% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.8%)
- BULLISH: Trading 77.1% below Wall St target ($7.67)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.87 -
$3.69
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.30
Resistance Level
$4.62
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.68
Wall Street Target
$7.67
(+77.1%)
Revenue Growth (YoY)
244.2%
Profit Margin
-115.1%
Share & Embed Analysis
Last updated: August 24, 2026 4:13 PM ET
Data refreshes hourly during market hours. Next update: 5:13 PM
Data refreshes hourly during market hours. Next update: 5:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OABI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles S Berkman
SELL
7157 shares
2026-04-07
Kurt A Gustafson
SELL
6913 shares
2026-04-07
Matthew W Foehr
SELL
19244 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 34 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 39 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 50 HOLD |
